InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,337.34
(
-2.01%
)
US TECH 100
17,847.38
(
-2.93%
)
Dow Jones
39,608.21
(
-1.83%
)
Brent Oil
76.96
(
-3.76%
)
Bitcoin
63,108.85
(
-3.43%
)
Post# of 252776
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ThomasS

Send PM Follow Ignore
Followers 12
Posts 2277
Boards Moderated 0
Alias Born 05/05/2005

ThomasS

Re: None

Thursday, 05/13/2010 8:15:22 AM

Thursday, May 13, 2010 8:15:22 AM

Post# of 252776
MNTA: Momenta Pharma can benefit from FDA rejection of Teva petition, says Oppenheimer
After the FDA rejected a petition from Teva (TEVA) to delay filings for generic versions of Copaxone, Oppenheimer believes the decision removes a roadblock to the approval of Momenta's (MNTA) generic version of the drug. The firm raised its target to $19 from $17 and maintains an Outperform rating

"If we don't succeed, we run the risk of failure."
-Dan Quayle

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up